Taxotere (Docetaxel)
The Taxotere MDL, centralized in the Eastern District of Louisiana in 2016 before Judge Jane Triche Milazzo, consolidates claims that the chemotherapy drug docetaxel, marketed as Taxotere, causes permanent alopecia in a meaningful share of patients who receive it, a risk plaintiffs allege was inadequately disclosed relative to comparable chemotherapy regimens. Centralization made sense because the claims share a common warning-adequacy theory and common questions about what the manufacturer knew about permanent hair-loss risk, and when, relative to the drug's labeling history.
With 81 actions still coordinated, this docket sits well past its early, claim-building phase. It has been through bellwether trial activity, which in a docket like this typically tests both the strength of the warning-adequacy theory and how juries value a permanent cosmetic and psychological injury arising from an otherwise medically necessary cancer treatment, a damages question that does not map cleanly onto more conventional physical-injury mass torts. That valuation question, more than any remaining general-causation dispute over whether docetaxel can cause permanent alopecia, is the more active driver of how remaining claims are likely to resolve.
Because the injury here does not involve an ongoing physical-treatment component tied to the wrongdoing itself, the docket's resolution dynamics are shaped more by individualized warning-history and diagnosis-timing evidence than by the kind of large-scale settlement-fund mechanics seen in some higher-volume device or drug dockets. For claims that do not settle, remand to the originating district for trial remains the applicable backstop, consistent with standard MDL procedure, informed by whatever bellwether-trial record has already been established in the transferee court.
Criterica Intelligence's platform reads this kind of distinctive injury-and-damages structure specifically, rather than assuming every drug-warning docket resolves the same way, across the full population of active MDLs.
The claims share a common warning-adequacy theory, that the manufacturer inadequately disclosed the risk of permanent alopecia relative to comparable chemotherapy regimens, and common questions about what it knew about that risk and when.
Less a remaining general-causation dispute over whether docetaxel can cause permanent hair loss, and more how juries and negotiators value a permanent cosmetic and psychological injury arising from an otherwise medically necessary cancer treatment.
Yes — the docket has moved through bellwether trial activity, which has tested both the warning-adequacy theory and how the claimed injury is valued, giving remaining claims an established record to be evaluated against.
It proceeds toward trial in its originating district following remand, informed by whatever bellwether-trial record has already been developed in the transferee court on warning-adequacy and damages.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.